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ABSTRACT
Introduction. The multimodality management of Ewing’s Sarcoma Family Tumors (ESFT) consists of neoadjuvant 
chemotherapy followed by local treatment: surgery, radiotherapy (RT) or a combination of both. The objectives of 
this study were to analyze disease control and overall survival in patients receiving radiotherapy as local treatment, 
as part of multimodality management of ESFT at our institute over a period of seven years.
Material and methods. This is a retrospective single institutional study. Hospital records were searched for 
patients with ESFT who received radiotherapy from January, 2012 to December, 2018. Forty-nine patients were 
found eligible and evaluated with respect to prognostic factors, treatment-related factors and outcomes. Time 
to event was measured from the date of diagnosis and survival curves were estimated by Kaplan-Meier method 
and log-rank test for comparison.
Results. Median follow up for patients was 18 months (range 3–81 months). Local failure/relapse was associated 
with worse survival. Five-year local control was 79.1% and overall survival 51.2% in the analyzed cohort. Local 
control did not differ significantly based on prognostic variables or treatment characteristics. Combined surgery 
and radiotherapy as local treatment along with good response to neoadjuvant chemotherapy were associated 
with significant improvement in overall survival (p-value < 0.05).
Conclusions. Combined modality local treatment with surgery and radiotherapy along with a favorable response to 
neoadjuvant chemotherapy are associated with improved survival in ESFT. For unresectable tumors, radiotherapy 
alone remains the optimum local treatment, albeit with inferior survival outcomes.
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Introduction
The Ewing’s Sarcoma Family of Tumors (ESFT) 
comprises of a group of primary bone and soft-tissue 
tumors that include classic Ewing’s sarcoma (os-
seous and extra-osseous), peripheral primitive 
neuroectodermal tumor (PNET) and Askin tumor 
of the chest wall. Histologically they are malignant 
small-round-blue-cell tumors, first described by James 
Ewing in 1921 [1]. Around 90% of patients have a ge-
netic translocation [t(11;22) or t(21;22)] involving the 
EWS and FLI1 genes and frequent expression of c-Myc 
proto-oncogene [2].
The incidence of Ewing-family tumors peaks in 
adolescence, is slightly more common in males, and 
commonly arises in the extremities [3]. It has a high 
incidence in the Western population while being rarer 
in Asia and Africa [4]. 
Ewing’s Sarcoma has a good prognosis nowa-
days with the advent of newer regimens of systemic 
therapy in combination with adequate local treatment 
[5–10]. Definitive local control of the primary tumor 
is a pre-requisite of cure, and local failures are associ-
ated with extremely poor prognosis. Local treatment 
modalities in Ewing’s sarcoma consist of surgery and/or 
radiotherapy (RT). Because of the radiosensitive nature 
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of this tumor, radiotherapy had been the local treatment 
of choice for many years. However, with better systemic 
control of disease, advances in orthopedic surgery and 
chances of second malignancy post irradiation, the use 
of radiotherapy in ESFT is gradually declining [11]. 
However, for lesions located in the axial skeleton or 
where surgery is not feasible, RT remains the sole op-
tion for local therapy.
In this single-institution retrospective study from 
North East India, we investigate the role of radiotherapy 
as local treatment in the multimodality management of 
ESFT patients. The objectives were to analyze disease 
control and overall survival in patients of this group of 
tumors receiving radiotherapy at our institute over the 
study period.
Material and methods
From the period of January, 2012 to December, 
2018, patients registered with diagnosis of Ewing’s 
Family Tumor in the hospital were assessed. All 
data were obtained from patients’ case files and 
Hospital-Based Cancer Registry records and all 
the analyzed data for this study are included in this 
published article. The study was approved by the 
Institutional Ethics Committee and because this was 
a retrospective study, the requirement of patients’ 
consent was waived.
Patients
Patients diagnosed as osseous or extra-osseous Ew-
ing’s Sarcoma, peripheral Primitive Neuro-Ectodermal 
Tumor (PNET) and Askin’s tumor of the chest wall 
with Immunohistochemistry confirmation (CD 99, 
FLI-1 positive) were considered for evaluation in this 
study. Those without IHC confirmation of tumors and 
who declined or defaulted treatment were excluded. 
Also, patients who did not receive radiotherapy as part 
of their local treatment were omitted from assessment in 
this study. A summary of cases evaluated and analyzed 
is shown in Figure 1.
Taking into consideration the above criteria, 49 pa-
tients were found eligible for retrospective review during 
the study period. Patient demographics, tumor char-
acteristics and treatment details for them were noted. 
Treatment and follow-up
The intent of treatment received was as per the 
decision of the Multidisciplinary Joint Tumor Board of 
the institute and all patients received treatment as per 
Ewing’s Family Tumor (EFT) protocol. Neoadjuvant 
Chemotherapy included two courses of Vincristine, 
Ifosfamide and Etoposide (VIE) 3 weekly followed by 
two courses of Vincristine, Adriamycin and Cyclophos-
phamide (VAC) 2 weekly. Local therapy in the form 
of surgery or radiotherapy or both, depending on the 
Figure 1. Schematic chart showing patient evaluation and analysis for the study
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location and resectability of the primary tumor, had to be 
offered between weeks 9 and 12 of treatment. Resectable 
tumors underwent surgery as the primary local treatment 
followed by adjuvant radiotherapy based on histopa-
thology and margin status. Borderline resectable cases 
after induction chemotherapy underwent pre-operative 
radiotherapy followed by surgery, whereas tumors which 
were found inoperable received radical radiotherapy 
alone as local treatment. Radiotherapy doses were 45 Gy 
pre-operatively, 50–54 Gy post-operatively and 50–60 Gy 
in radical setting (at 180–200 cGy per fraction). Mainte-
nance therapy after local treatment consisted of 3 weekly 
chemotherapy with 4 cycles of VAC, 2 cycles of VIE and 
6 cycles of VCD – Actinomycin D replacing Doxorubicin 
after a cumulative dose of 360 mg/m2. Vincristine was 
given weekly throughout the chemotherapy schedule and 
also along with radiotherapy [12]. 
Treatment records of patients were evaluated for 
details of chemotherapy, surgery and radiotherapy re-
ceived by them. Follow up details of local examination 
and imaging of primary site as well as metastasis was 
also noted. Response to induction chemotherapy was 
assessed from the surgical specimen in resected cases 
and by imaging in unresected cases.
Outcome analysis  
Response to treatment was classified as per the 
revised Response Evaluation Criteria In Solid Tumors 
(RECIST) 1.1 [13]. A good response to induction 
chemotherapy was classified as > 90% necrosis in 
resected specimen in patients who underwent surgery 
and a complete or partial response in the tumor site for 
unresectable cases. 
Tumors with complete or partial response or stable 
disease at the primary site without appearance of new 
metastatic lesions were considered locally controlled. 
Disease progression was defined as clinical or radio-
graphic increase in the size of primary or metastatic 
tumor or appearance of new metastatic lesion. Overall 
survival (OS) was defined as the time interval from 
diagnosis till death.
Statistical analysis
SPSS version 19 (IBM Company Copyright 
1989, 2010 SPSS, Inc.) was used for statistical analy-
sis. Chi-square test was used to evaluate treatment 
and prognostic factors for local control. Survival and 
local control rates were calculated using Kaplan-Meier 
estimation and log-rank test was used for group com-
parisons. A Cox proportional hazards model was used 
to clarify independent predictive factor in multivariate 
analysis. Statistical significance was defined as a p-value 
of < 0.05.
Results
The median follow up of entire cohort was 18 months 
(Range 3–81 months). The various patient- and tu-
mor-related variables of the study are shown in Table 1.
Patient characteristics
The mean age of patients was 15.29 years (SD: 10.13), 
with 53.1% patients aged 10–19 years and Male:Female 
ratio of 1.7:1. The median duration of symptoms among 
the patients was 5 months (Range: 1–12 months).
Tumor characteristics
The mean tumor size was 9.09 cm (SD = 3.44). The 
majority of cases showed presence of a soft tissue mass 
(85.7%) with radiological evidence of tumor necrosis in 
34.6%. Most common sites of tumor location were the 
femur and pelvis (n = 7, 14.3% each). Most of tumors 
had skeletal origin (73.5%) and were centrally located 
(61.2%). Four patients (8.2%) had metastatic disease 
at diagnosis with bone metastasis being most common 
(3 cases).
Treatment characteristics
All 49 patients included in the study were planned 
with intent to cure or salvage (Fig. 1). Neoadjuvant 
chemotherapy was received by all except one patient. 
Surgery as local treatment was used in 14 cases, with 
11 patients undergoing complete resection with clear 
margins (R0) while 3 had marginal/intralesional re-
section of their tumors. All patients that underwent 
surgery also received radiotherapy — 5 preoperative 
and 9 postoperatively.
Radiotherapy was the definitive local therapy 
planned in 71.4% (35/49) of our patients. Among 
them, a dose of 54 Gy or above was used in 28 patients, 
5 patients received less than 54 Gy and 2 patients died 
before radiotherapy completion (one each from sepsis 
and disease progression). Radiotherapy was delivered 
using conventional planning techniques in majority 
(63.2%) of the patients (Tab. 1). 
Local control and survival analysis
The 2 patients of ESFT who could not complete 
planned radiotherapy treatment were omitted from 
survival and disease specific analysis and hence the total 
number of cases for final evaluation was 47. The 5-year 
local control and overall survival for the study group 
was found to be 79.1% and 51.2%, respectively (Fig. 2). 
An important prognostic indicator of better survival 
was achievement of local disease control. Cases where 
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Table 1. Patient and tumor related characteristics
Variables n (%)
Age
     < 18 years




     Male




     < 6 months




     CT Scan
     MRI





     Less than 8 cm




     Skeletal




     Central




     Yes




     Yes




     Conventional
     3DCRT




CT — computed tomography; MRI — magnetic resonance imaging; PET-CT 
— positron emission tomography-computed tomography; NACT — neo-
adjuvant chemotherapy; 3DCRT — 3-Dimensional conformal radiotherapy; 
IMRT — intensity modulated radiation therapy
Figure 2. Kaplan-Meier curves showing local control (A) and 
overall survival (B) of study group (n = 47) 
primary tumor was locally controlled following multi-
modality therapy had significantly better 5-year overall 
survival (53.3% v. 33.3%, p = 0.038, Fig. 3). 
Univariate analysis of the patient-, tumour- and 
treatment-related characteristics with local control was 
carried out and is depicted in Table 2. Univariate and 
multivariate analysis of various prognostic factors with 
survival for these patients are shown in Table 3.
Local control rates did not differ significantly 
among the different enlisted prognostic variables (all 
p-values > 0.05). A subset analysis was performed to 
look into the impact of local treatment modality with 
respect to tumor size (< 8 cm v. 8 cm and above) and lo-
cation (central vs peripheral), which is shown in Figure 4. 
Local control with combined surgery and radiotherapy 
was better compared to definite radiotherapy irrespec-
tive of these variables, but the difference was statisti-
cally insignificant.
A favorable response to neoadjuvant chemotherapy 
(p-value = 0.044) and combined surgery and radio-
therapy as local treatment therapy (p-value = 0.022) 
were also associated with better survival in patients 
with non-metastatic ESFT. On multivariate analysis, 
response to neoadjuvant chemotherapy was found to 
be the only independent prognostic factor for OS (HR: 
0.301, 95% CI: 0.093–0.970, p-value: 0.044). 
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Figure 3. Kaplan-Meier curves showing overall survival based 
on local disease control status for study group (n = 49)
Table 2. Univariate analysis of local control of the localized Ewing’s Sarcoma Family Tumor cases
Variables n (%) Univariate Analysis
5-year Local Control (%) p-value
Age
     < 18 years







     < 8 cm







     Central







     Yes






Type of Local Treatment
     Surgery + RT






RT Dose (Definitive RT only)
     < 54 Gray






NACT — neoadjuvant chemotherapy; RT — radiotherapy
Discussion
ESFTs are comparatively rare in Asian population 
[4, 14]. Chakraborty et al. [15] reported that ESFT 
comprises 15% of all bone malignancies in India. 
They found 68% of the cases in 0–19 years age group 
with male preponderance (1.6:1) and a higher risk of 
tumor in the bones of limbs (1.6 times) compared 
to other bones. Our findings (Tab. 1) correlate with 
their observation except that most of our cases had 
tumors located in the axial skeleton and pelvis (61.2%) 
rather than in the limb bones. The median duration 
from symptoms to definitive diagnosis in our patients 
was 5 months, which correlates with the findings by 
Sneppen et al. [16] who reported a median duration 
of 3 to 9 months. The majority of patients in our study 
(59.2%) had large tumor size (≥ 8 cm) which is an es-
tablished poor prognostic factor [9, 17, 18]. Another 
observation to be noted was the high percentage of 
patients with good response to neoadjuvant chemo-
therapy (76.5%) — a prognostic indicator of better 
survival [19–21]. Around one fourth of Ewing’s sarcoma 
patients have metastatic disease upfront and often 
show a dismal prognosis. [3] In our study, however, the 
proportion of metastatic cases were low (n = 4, 8.2%). 
This was because the majority of metastatic ESFT cases 
often presented with poor general condition and hence 
received palliative therapy, which made them ineligible 
for inclusion in this study.
The role of chemotherapy in successful treatment of 
ESFT has evolved considerably over last few decades and 
is still evolving. [12] The Intergroup Ewing’s Sarcoma 
Studies (IESS) I and II [5, 6] and the study by Grier et al. 
[7] established the role of multidrug chemotherapy in the 
management of ESFT. The Childrens Oncology Group 
AEWS-0031 study [8] subsequently demonstrated the 
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Table 3. Univariate and Multivariate Analysis of Overall Survival of the Localized ESFT cases
Prognostic Factors n (%) Univariate Analysis Multivariate Analysis
5-year OS (%) p-value HR (95% CI) p-value
Age
     < 18 years





0.96 1.020 (0.273–3.809) 0.977
Tumor Size
     < 8 cm





0.264 2.205 (0.627–7.753) 0.218
Tumor Location
     Central





0.055 0.283 (0.076–1.055) 0.060
Duration of Symptoms
     < 6 months





0.463 1.302 (0.453–3.743) 0.624
Response to NACT
     No





0.044 0.301 (0.093–0.970) 0.044
Type of Local Treatment
     Surgery + RT





0.022 0.387 (0.079–1.887) 0.240
NACT — neoadjuvant chemotherapy; RT — radiotherapy; OS — overall survival; HR — hazard ratio; CI — confidence interval
benefit of dose intensification and interval compression 
of chemotherapy regimen without increased toxicity. 
So, the current standard of care is initial cytoreductive 
chemotherapy to eliminate micrometastasis followed 
by local therapy of primary disease and then consolida-
tion chemotherapy to reduce tumor recurrence. In our 
study, all but one patient received treatment as per the 
Ewing Family of Tumors 2001 protocol. One patient did 
not receive neoadjuvant chemotherapy but underwent 
upfront surgery followed by adjuvant radiotherapy and 
chemotherapy. The reason for declining neoadjuvant 
chemotherapy for this patient could not be ascertained 
owing to the retrospective nature of this study. 
Effective local treatment of the primary tumor plays 
a crucial role in the outcome of ESFT patients. In our 
study, local control showed significant correlation with 
survival: 5 year overall survival 53.3% in locally con-
trolled patients as opposed to 33.3% in local failures 
or relapsed cases (p-value = 0.038). Till date, there 
are no randomized controlled trials comparing surgery 
versus radiotherapy in ESFT and all data available are 
retrospective in nature [9, 17, 18]. 
Schuck et al. [9] reviewed 1058 patients of localized 
ESFT for the impact of local therapy on local control 
and event free survival. Definitive radiotherapy showed 
higher incidence of local failure and poorer EFS after 
5 years as compared to surgery with or without radio-
therapy groups (p value < 0.05). They also demonstrated 
that intralesional or debulking surgeries followed by ad-
juvant radiotherapy offered no advantage over definitive 
radiotherapy and hence should be avoided.
Choi et al. [17] from South Korea reviewed 91 local-
ized ESFT patients and reported higher local control 
rates with combined surgery and radiotherapy versus de-
finitive radiotherapy (90.2% v. 64.8%, p value = 0.052). 
The superiority was found to be significant for tumors 
8 cm or more in size (p value= 0.033) but not for smaller 
tumors (p value = 0.374). 
Biswas et al. [18] in a single institution retrospective 
review have published the largest reported data on local-
ized ESFT (224 cases) from India. They observed 5-year 
overall survival of 52.4% (± 4.3%) and local control 
rate of 63% (± 4.3%). On subgroup analysis, combined 
surgery and radiotherapy showed a hazard ratio of 2.5 
(95% CI 1.2–5.19, p-valu e= 0.01) compared to radio-
therapy alone for local control and also significantly 
improved 5-year event-free survival (50.4% v. 32.1%) 
and overall survival (69.1% v. 46.9%).
In our study, ESFT cases (n = 47) showed a 5-year 
local control rate of 79.1% and overall survival of 52.1%. 
Local control rates did not differ significantly among the 
various prognostic groups like age, tumor size, tumor 
location or response to neoadjuvant chemotherapy (all 
p-values > 0.05) as shown in Table 2. Fourteen patients 
(29.8%) underwent resection of their tumors in our 
study — 5 patients received radiation preoperatively and 
9 patients postoperatively. Radiotherapy was delivered 
preoperatively in large tumors of resectable locations 
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Figure 4. Subset analysis of local control according to treatment methods: Surgery and adjuvant radiotherapy versus radiotherapy 
alone; A. Comparison based on tumor location: central versus peripheral; B. Comparison based on tumor size: less than 8 cm 
versus 8 cm and above; LC — local control; RT — radiotherapy
(e.g. distal extremity) while the indications of postopera-
tive radiotherapy were positive/close margins and poor 
histologic response (< 90% necrosis in resected tumor) 
after chemotherapy [9, 10, 22]. Surgery and RT showed 
superior local control rates than RT alone (92.3% versus 
71%, p-value = 0.214), although the difference was not 
statistically significant unlike the results of Schuck et al. 
[9] and Biswas et al. [18].
A multitude of factors determine the choice of local 
therapy in ESFT. Smaller tumors in favorable locations 
(e.g. distal extremities) with significant response follow-
ing neoadjuvant chemotherapy are treated more often 
with surgery. Tumors of large size or in central location 
(paravertebral, pelvic primaries) end up being treated 
with definitive radiotherapy. So we performed a subset 
analysis of local control according to local treatment 
modality with respect to tumor size (< 8 cm v. 8 cm and 
larger) and location (central versus peripheral). Among 
central tumors 25% (7/28) underwent resection, while 
for peripheral tumors the resection rate was 36.8% 
(7/19). With regards to tumor size, 21.4% (6/28) with 
dimension 8 cm or more underwent surgery while for 
tumors less than 8 cm size the rate of surgery was 42.1% 
(8/19). It was observed that local treatment with surgery 
and radiotherapy combined resulted in better 5-year lo-
cal control rates than definitive radiotherapy alone for 
ESFT irrespective of tumor size and location (Fig. 4), 
even though statistical significance (all p-values > 0.05) 
was lacking. However, it must be understood that surgery 
as local treatment modality in ESFT requires special 
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expertise, especially in young children with growing 
bones. For tumors in critical locations like in the axial 
skeleton or advanced tumors in limbs, an organ pres-
ervation approach is often not feasible with surgery. 
Definitive radiotherapy remains the only local treatment 
option for such cases [23]. It can be expected that with 
the use of better imaging and treatment planning, newer 
techniques of precise radiation delivery and daily image 
guidance for treatment, radiotherapy to high doses can 
be safely and effectively delivered for optimum outcome 
in ESFT patients.
Patients receiving combined modality local therapy 
also had improved survival compared to radiotherapy 
alone (83.3% v. 31.1%, p = 0.022) as seen in results 
of our study (Tab. 3). Good response to neoadjuvant 
chemotherapy was another prognostic factor that 
translated into improved OS on both univariate and 
multivariate analysis (hazard ratio 0.301, 95% CI: 
0.093–0.970, p = 0.044). Thus our study also shows that 
ESFT cases which respond favorably to cytoreductive 
chemotherapy and subjected to combined modality lo-
cal treatment have significantly improved survival, even 
though the difference was not forthcoming in terms of 
local control.
Ours is a single institution retrospective review from 
a resource constrained region of the world, yet the re-
sults are not far from the studies in western population 
[4, 5, 11] and also correlate well with reports from Asia 
[17] and India [18]. However, our study is not without 
its limitations. There is a high rate of non-compliance 
to treatment among our patients, an issue that has 
previously been analyzed in pediatric population of 
our region by Hazarika et al. [24] who found that resi-
dence in rural areas, lack of maternal education, low 
socioeconomic status, age > 5 years and female sex 
were associated with higher risk of treatment abandon-
ment. As evident from Figure 1, the non-compliance to 
diagnosis and treatment was 21% (15/72) in this study. 
Also, many patients could not receive treatment with 
curative intent and hence the final analysis of disease 
control and survival could be carried out for a cohort 
of 47 patients in our study. As a consequence of limited 
sample size, specific subset analysis based on tumor 
site, stage and patterns of failure could not be carried 
out in this study.
The retrospective nature of this study invariably 
allows for bias in choosing surgery versus radiotherapy 
as local treatment modality which might have affected 
the final outcome. There is a need for a randomized 
controlled trial to address this issue. However, in light of 
the available data demonstrating superiority of surgery 
over radiotherapy and also with the rapid advances in 
surgical techniques, whether any leading group in the 
world comes forward with such a comparative rand-
omized trial remains to be seen.
Conclusions
Effective primary control significantly improves sur-
vival in ESFT. Favorable tumor response to neoadjuvant 
chemotherapy is also an independent prognostic factor 
that translates into better outcomes in ESFT as ob-
served in our study. Our study results demonstrate that 
combined surgery and radiotherapy as local treatment 
provides better overall survival in these patients. How-
ever, for unresectable tumors definitive radiotherapy 
remains the only option which also can achieve effective 
local control, albeit with inferior survival rates. Thus 
a multidisciplinary treatment approach based on the 
prognostic factors and functional outcome should 
be made for optimum results. Radiotherapy, with or 
without surgery, remains an important component to 
achieving better local control in patients with ESFT.
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